Back to all Current clinical trials
and
• Have been diagnosed with Type 1 Myotonic Dystrophy
The study will be conducted in cohorts. The cohort you are assigned to, will depend on the timing of when you enter the study.
Around 80 participants will take part worldwide, with the study running for approximately eight months. Participation includes scheduled visits with the Mater Research team, blood tests, physiotherapy assessments, and a small number of overnight stays at Mater Private Hospital. By joining, participants will play a vital role in advancing research for DM1 and helping improve future treatment options.
Back to all Current clinical trials
ADO-DM1 - Do you have Type 1 Myotonic Dystrophy?
Mater Hospital Brisbane, in partnership with Arrowhead Pharmaceuticals, is inviting Queenslanders living with Type 1 Myotonic Dystrophy (DM1) to take part in an important clinical research study. This study is testing a new investigational treatment, ARO-DM1, to see whether it may help slow disease progression and improve muscle strength and daily function.
What you need to know
You may be eligible if you:
• Are aged between 18 - 65 years oldand
• Have been diagnosed with Type 1 Myotonic Dystrophy
What is involved for me?
The study will be conducted in cohorts. The cohort you are assigned to, will depend on the timing of when you enter the study. Around 80 participants will take part worldwide, with the study running for approximately eight months. Participation includes scheduled visits with the Mater Research team, blood tests, physiotherapy assessments, and a small number of overnight stays at Mater Private Hospital. By joining, participants will play a vital role in advancing research for DM1 and helping improve future treatment options.
